Skip to main content
. Author manuscript; available in PMC: 2012 Nov 30.
Published in final edited form as: Oncogene. 2011 Oct 10;31(22):2738–2749. doi: 10.1038/onc.2011.454

Figure 4. ABT-737, a Bcl-2 antagonist, restores and induces sensitivity to 2DG.

Figure 4

(A) TCLs with Bcl-2 overexpression were treated as indicated with 2DG and ABT-737 (0.5 μM). Viability was assessed by Guava ViaCount at the times indicated. Data represent average viabilities ± S.D. (B) Non-transduced TCLs were treated as indicated with 2DG and ABT-737 (0.5 μM) for 24 hours. Viability was assessed by Guava ViaCount. Data represent average viabilities ± S.D.